Artelo Biosciences, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Artelo is a clinical-stage biopharmaceutical company developing therapies targeting lipid-signaling pathways, including the endocannabinoid system. It has no approved products and has not generated revenue.
Financial performance and liquidity
Amounts below are in thousands of U.S. dollars, except per-share data.
- Revenue: None. The filing says product or other revenue is not expected in the near future.
- Operating expenses: $2,292, up $346 from $1,946 in Q1 2022. R&D was $1,235 versus $464; general and administrative expense was $1,057 versus $1,482.
- Loss: Operating loss was $2,292 versus $1,946; net loss was $2,168 versus $1,965. Basic and diluted loss per share was $0.76 versus $0.70.
- Cash flow: Operating cash use was $2,186 versus $2,053. Investing activities provided $2,199, largely reflecting marketable-security sales and maturities, partly offset by purchases. No financing cash flows were reported.
- Cash and investments: Cash and cash equivalents were $6,916 at quarter-end; trading marketable securities were $8,567. Current assets totaled $16,386, against current liabilities of $825, for working capital of $15,561.
- Debt and liquidity: The balance sheet reports no borrowings; lease liabilities totaled $52. Management expects existing resources to fund planned operations into the second half of 2024, but says additional financing or licensing will be needed to continue beyond that period. The $20 million equity line had no sales as of March 31, 2023.
Material changes and business developments
- Net loss increased by $203 year over year. R&D expense rose by $771; management attributes the increase partly to UK R&D tax credits that had reduced prior-year expense but had not yet been received in the current period. Lower G&A expense, including lower stock-based compensation, partly offset the increase.
- Current assets declined by $1,936 from December 31, 2022, primarily due to the maturity of available-for-sale securities; working capital declined by $1,763.
- Artelo completed enrollment in the Phase 1b stage of its CAReS trial of ART27.13 for cancer-related anorexia during Q1. It initiated the Phase 2a stage in the UK in April 2023, after quarter-end, with a planned 40-patient study and 3:1 randomization.
- ART26.12, a FABP5 inhibitor, is in regulatory-enabling preclinical work, with first-in-human studies anticipated in the second half of 2024, subject to study resources and regulatory review. ART12.11, a CBD cocrystal, remains preclinical.
Outlook, risks and other notable items
- The company expects continuing operating losses and does not expect near-term profitability. Funding beyond the stated runway may require equity or debt financing, licensing, or other arrangements; financing may be unavailable or dilutive.
- UK R&D tax-credit rules may reduce relief, including for certain trial activity outside the UK from April 2024. Changes to the relief regime could increase development costs.
- Key risks include clinical and regulatory uncertainty, trial enrollment or supply delays, reliance on third-party research and manufacturing providers, licensing and intellectual-property obligations, controlled-substance regulation, and the ability to raise capital.
- Approximately $6.3 million of bank deposits exceeded the federal insurance limit at March 31, 2023. Management stated it considered related credit risk not significant.
- Research and development contracts may require additional payments depending on program progress and milestones. Management reported no legal proceedings likely to have a material adverse effect.
- Disclosure controls were assessed as effective at a reasonable-assurance level; no material change in internal control over financial reporting was reported.
Investor verification points
- Track cash burn, marketable-security balances, and whether the stated runway into the second half of 2024 remains achievable.
- Verify subsequent use and availability of the $20 million equity line, and assess potential dilution or other financing needs.
- Monitor CAReS Phase 2a enrollment, timing, and clinical results, as well as progress toward ART26.12 enabling studies.
- Check the timing and amount of UK R&D tax credits and the impact of the announced rule changes on development costs.
- Review future disclosures on clinical-trial commitments, milestone payments, third-party supply, and license compliance.